Yi Chen

List of Publications by Year in descending order

60 papers	1,840 citations	279798 23 h-index	289244 40 g-index
67 all docs	67 docs citations	67 times ranked	3212 citing authors

#	Article	IF	Citations
1	Iron Metabolism in Cancer. International Journal of Molecular Sciences, 2019, 20, 95.	4.1	179
2	Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell, 2018, 175, 186-199.e19.	28.9	166
3	Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell, 2016, 30, 459-473.	16.8	117
4	TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling. Nature Communications, 2019, 10, 2863.	12.8	114
5	Molecularly precise self-assembly of theranostic nanoprobes within a single-molecular framework for in vivo tracking of tumor-specific chemotherapy. Chemical Science, 2018, 9, 4959-4969.	7.4	81
6	G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nature Communications, 2017, 8, 274.	12.8	74
7	Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Oncotarget, 2015, 6, 2917-2927.	1.8	60
8	10-Boronic acid substituted camptothecin as prodrug of SN-38. European Journal of Medicinal Chemistry, 2016, 116, 84-89.	5.5	51
9	c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Research, 2015, 75, 4548-4559.	0.9	47
10	Discovery of JND3229 as a New EGFR^{C797S} Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Medicinal Chemistry Letters, 2018, 9, 1123-1127.	2.8	46
11	Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer Letters, 2017, 386, 47-56.	7.2	45
12	Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Molecular Cancer, 2020, 19, 90.	19.2	44
13	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology, 2017, 65, 1948-1962.	7.3	43
14	Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. European Journal of Medicinal Chemistry, 2018, 145, 389-403.	5.5	40
15	Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. Acta Pharmaceutica Sinica B, 2021, 11, 1365-1378.	12.0	38
16	Antiangiogenic activity of 11,11â€²-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola. Biochemical and Biophysical Research Communications, 2005, 329, 1334-1342.	2.1	37
17	Dual targeting of microtubule and topoisomerase II by Î±-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget, 2015, 6, 8960-8973.	1.8	35
18	Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget, 2017, 8, 4156-4168.	1.8	31

#	Article	IF	Citations
19	Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica, 2016, 37, 1481-1489.	6.1	30
20	c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. Clinical Cancer Research, 2017, 23, 974-984.	7.0	27
21	Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities. ACS Medicinal Chemistry Letters, 2014, 5, 304-308.	2.8	26
22	Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors. Acta Pharmacologica Sinica, 2017, 38, 1038-1047.	6.1	26
23	The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11â€²-dideoxyverticillin-induced G2/M arrest. FEBS Letters, 2005, 579, 3683-3690.	2.8	25
24	Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models. Journal of Experimental and Clinical Cancer Research, 2019, 38, 372.	8.6	25
25	Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 804-815.	6.4	25
26	G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. Theranostics, 2018, 8, 2884-2895.	10.0	24
27	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Molecular Cancer Therapeutics, 2018, 17, 751-762.	4.1	22
28	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro. Bioorganic and Medicinal Chemistry, 2019, 27, 1405-1413.	3.0	20
29	Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamat (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. European Journal of Medicinal Chemistry, 2021, 209, 112913.	5.5	20
30	AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition. Acta Pharmacologica Sinica, 2019, 40, 1587-1595.	6.1	19
31	Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced inÂvivo efficacy for cancer therapy. European Journal of Medicinal Chemistry, 2017, 138, 514-531.	5.5	18
32	C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacologica Sinica, 2019, 40, 823-832.	6.1	18
33	G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation. Acta Pharmacologica Sinica, 2014, 35, 1546-1555.	6.1	17
34	G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspase-dependent apoptosis in human breast cancer cells in vitro. Acta Pharmacologica Sinica, 2014, 35, 1055-1064.	6.1	16
35	SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy. Journal of Controlled Release, 2021, 339, 297-306.	9.9	16
36	Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacologica Sinica, 2014, 35, 89-97.	6.1	15

#	Article	IF	Citations
37	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3KÎ±-selective inhibitor CYH33 in breast cancer. Cancer Letters, 2018, 433, 273-282.	7.2	15
38	Design, synthesis and biological evaluation of novel homocamptothecin analogues as potent antitumor agents. Bioorganic and Medicinal Chemistry, 2015, 23, 1950-1962.	3.0	14
39	A series of camptothecin prodrugs exhibit HDAC inhibition activity. Bioorganic and Medicinal Chemistry, 2018, 26, 4706-4715.	3.0	14
40	Semisynthesis of triptolide analogues: Effect of B-ring substituents on cytotoxic activities. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5671-5674.	2.2	13
41	Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3KÎ±-selective Inhibitors in Breast Cancer. Theranostics, 2017, 7, 974-986.	10.0	12
42	Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2018, 148, 140-153.	5.5	12
43	Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127710.	2.2	12
44	Design, Synthesis, and Biological Evaluation of HSP90 Inhibitorâ€“SN38 Conjugates for Targeted Drug Accumulation. Journal of Medicinal Chemistry, 2020, 63, 5421-5441.	6.4	11
45	Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition. MedChemComm, 2012, 3, 1423.	3.4	10
46	The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors. Molecular Cancer Therapeutics, 2019, 18, 667-679.	4.1	10
47	Repressing MYC by targeting BET synergizes with selective inhibition of PI3KÎ± against B cell lymphoma. Cancer Letters, 2022, 524, 206-218.	7.2	9
48	Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. European Journal of Medicinal Chemistry, 2018, 152, 298-306.	5.5	8
49	Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR. European Journal of Medicinal Chemistry, 2018, 158, 428-441.	5.5	8
50	Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects. ACS Omega, 2020, 5, 350-357.	3.5	7
51	SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-METâ€“Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 36-45.	2.5	6
52	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. Haematologica, 2020, 105, 1021-1031.	3.5	6
53	The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation. Molecular Cancer Therapeutics, 2021, 20, 2198-2206.	4.1	6
54	Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer. Acta Pharmacologica Sinica, 2017, 38, 1533-1542.	6.1	5

#	Article	IF	Citations
55	Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads. Molecules, 2017, 22, 788.	3.8	5
56	Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors. European Journal of Medicinal Chemistry, 2022, 233, 114249.	5.5	5
57	PI3KÎ± inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2021, 6, 130.	17.1	4
58	SAF-248, a novel PI3KÎ´-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. Acta Pharmacologica Sinica, 2022, 43, 209-219.	6.1	3
59	The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKÎ± and overcomes gefitinib resistance in non-small cell lung cancer. Cancer Biology and Medicine, 2022, , 1-1.	3.0	2
60	Back Cover: Discovery of 3H-Imidazo[4,5-b]pyridines as Potent c-Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation (ChemMedChem 6/2012). ChemMedChem, 2012, 7, 1129-1129.	3.2	0